Avicanna appoints Eileen McCormack to board of directors
by CM Staff
Ms. McCormack has experience in bio-pharmaceutical product development, portfolio strategy in complex regulated environments and brings multi-market and international commercial experience.
TORONTO — Avicanna Inc. has appointed Eileen McCormack to its board of directors effective immediately. This announcement was made in conjunction with the resignation of Setu Purohit.
Avicanna stated that Eileen McCormack is an experienced senior marketing executive with more than 30 years of international experience in the bio-pharmaceutical industry. Ms. McCormack retired from AstraZeneca US where she led commercial and cross-functional teams responsible for launch planning and business development in the US market.
The company also stated that Ms. McCormack has experience in bio-pharmaceutical product development, portfolio strategy in complex regulated environments and brings multi-market and international commercial experience. Ms. McCormack gives back to her community by having served on a number of national and Toronto-based non-for-profit boards over the last 10 years.
“I am excited to be joining the Avicanna board of directors,” said Eileen McCormack in a statement.
“I believe Avicanna has a strong business model and talented management team that uniquely positions it to capitalize on the evolving cannabinoid-based biopharmaceutical industry. I look forward to contributing to Avicanna’s future growth and success as the company executes development and launch activities for its evidence-based products.”
“We are pleased to add Ms. McCormack to our board of directors at an appropriate time where her experience and wisdom can support the next phase of evolution of the company, including pipeline analysis and global commercialization efforts,” said Aras Azadian, CEO Avicanna Inc. in a statement.
